A meta-analysis focusing on the transcriptome assessment of EAT in CAD patients confirmed the activation of inflammatory, immune, and metabolic pathways in CAD–EAT, and highlighted interleukin-6 (IL-6) and tumor protein p53 (TP53) as core genes (Maghbooli and Hossein-Nezhad, 2015). The gene discussed is TP53; the disease is coronary artery disorder.